Study of PPAR-gamma activating effect of angiotensin II receptor antagonist, telmisartan

Study of PPAR-gamma activating effect of angiotensin II receptor antagonist, telmisartan - PPAR-gamma activating effect of angiotensin II receptor antagonist

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014248

Enrollment

Registered

2014-06-12

Start date

2014-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

# Telmisartan, 20mg/day # Dose will be increased (MAX 80mg/day) until clinical blood pressure is lowered less than 140/90 mmHg. # Six months # Olmesartan, 10mg/day # Dose will be increased (MAX 40m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hypertensive patients who were either never treated or treated with amlodipine alone 2) More than two months without any change in treatment, including amlodipine 3) All concomitant disease are stable 4) Patients who can give written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients treated with Ca-channel blockers (excluded amlodipine), ARB, angiotensin converting enzyme inhibitors, statin, anti-diabetic drugs, beta-blockers or thiazide diuretics 2) Patients with hypersensitivity to the drug contents 3) Pregnant women 4) Patients with severe renal dysfunction 5) Patients with secondary hypertension 6) Patients who are disqualified by the doctor

Design outcomes

Primary

Measure	Time frame
An increase of sRAGE concentration in blood	—

Countries

Japan

Contacts

Public ContactKentaro Ushijima

Jichi Medical University Division of Clinical Pharmacology

ushijima-kentarou@umin.ac.jp0285-58-7388

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026